Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Zimulti’s Outlook Be Affected By Suicidality Signal?

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will address psychiatric and neurological profiles of Sanofi-Aventis’ rimonabant for weight management.

You may also be interested in...



Merck To Focus Taranabant Development On Lower Dose

Cannabinoid-1 receptor blocker shows weight loss benefits with lower adverse psychiatric events at 2 mg dose in Phase III.

Merck To Focus Taranabant Development On Lower Dose

Cannabinoid-1 receptor blocker shows weight loss benefits with lower adverse psychiatric events at 2 mg dose in Phase III.

Sanofi Withdraws Zimulti NDA For Weight Loss

Company cites confusion over concerns raised by the Endocrinologic and Metabolic Drugs Advisory Committee, which voted against approval June 13.

Topics

UsernamePublicRestriction

Register

LL1135975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel